IL2 and neoplasm: The pioneering work published about 18 years ago [2] described an ex vivo genetically engineered xenogeneic cell gene therapy approach where the effects of repeated peritumoral local injections of human interleukin-2 (hIL-2) secreting Vero cells after surgical removal of the tumor followed by 60Co-radiotherapy were evaluated.